NANOIDROPS

Nucleic acid nanoparticles for topical ophthalmic drug delivery

Coordinatore	RIJKSUNIVERSITEIT GRONINGEN    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	168˙224 €
EC contributo	150˙000 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2013-PoC
Funding Scheme	CSA-SA(POC)
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-02-01   -   2015-01-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	RIJKSUNIVERSITEIT GRONINGEN  Organization address address: Broerstraat 5 city: GRONINGEN postcode: 9712CP contact info Nome: Dick Cognome: Veldhuis Email: send email Telefono: +31 503634142 Fax: +31 50 363 4500	NL (GRONINGEN)	hostInstitution	150˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Treatment of eye diseases is severely hindered by the tear fluid and eye lid movement removing the drug. As a consequence, very frequent administration of highly concentrated eye drops is necessary, causing substantial side effects. These side effects occur very often and can range from simple irritations to life threatening anaphylactic shocks in extreme cases. The other shortcoming in treating eye-related diseases is poor compliance, due to frequent dosing. We have developed a drug carrier system for eye drops that have high affinity to the cornea. This allows for a drastically lower concentration of the active compound and less frequent administration. A lower regime results in a better compliance, a higher effectiveness of the drug and less side effects. These nanoparticles can be combined with a wide variety of ophthalmic drugs, including the ones that have been abandoned due to severe side effects. Our approach has been proven during preclinical studies in rat models and even human tissue using two nanoparticle-antibiotic combinations that have shown exceptionally long lasting survival times on the eye of up to four hours. In this project we would like to complete our set of preclinical data regarding efficacy, scope and toxicity of the carrier to achieve commercialization of the drug delivery system.'